Evidence map›Paper›PMID 41649216›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Outstanding 1200 °C Oxidation Resistance in a Novel Multi-Principal Element Alloy via Lattice Distortion-Induced Diffusion Suppression.

Xinyu Zhang, Weiyan Lv, Xinguang Wang, Chuanmin Jia, Yizhou Zhou, Keqiang Qiu, Jianqiang Wang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinyu ZhangShenyang National Laboratory for Materials Science, Institute of Metal Research, CAS, Shenyang, P. R. China.
Weiyan LvShenyang National Laboratory for Materials Science, Institute of Metal Research, CAS, Shenyang, P. R. China.
Xinguang WangShenyang National Laboratory for Materials Science, Institute of Metal Research, CAS, Shenyang, P. R. China.
Chuanmin JiaWangxuan Institute of Computer Technology, Peking University, Beijing, P.R. China.
Yizhou ZhouShenyang National Laboratory for Materials Science, Institute of Metal Research, CAS, Shenyang, P. R. China.
Keqiang QiuSchool of Materials Science and Engineering, Shenyang University of Technology, Shenyang, P.R. China.
Jianqiang WangShenyang National Laboratory for Materials Science, Institute of Metal Research, CAS, Shenyang, P. R. China.ORCID https://orcid.org/0000-0001-8344-1343

Funding

National Natural Science Foundation of China 52171163National Natural Science Foundation of China 52471186Strategic Priority Research Program of Chinese Academy of Sciences XDA0410404
6 · The paper itself

Abstract

The ongoing demand for high-thrust turbine engines necessitates the advance of next-generation structural materials capable of withstanding higher temperatures. Commercial MCrAlY alloy, used as bond coats crucial for thermal barrier coating (TBC) systems, face a fundamental temperature ceiling of ∼1100 °C due to accelerated oxidation and spallation. Here, we design a novel Y and Hf co-doped NiCoCrAl-type multi-principal element alloy (MPEA) that achieves exceptional 1200 °C oxidation resistance primarily through lattice distortion-induced diffusion suppression. Compared with typical NiCoCrAlY alloy, the MPEA exhibits 59% lower in thermally grown oxide (TGO) growth rate, as well as negligible TGO spallation after 500 h at 1200°C. This performance stems from a significantly refined eutectic structure enabling rapid formation of a protective Al

Indexed as

1200 °C oxidation resistancelattice distortionmulti‐principal element alloyselective oxidation

Identifiers

PMID41649216
PMCPMC13067856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.